Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy
Тип публикации: Journal Article
Дата публикации: 2017-08-01
scimago Q1
wos Q1
БС1
SJR: 2.756
CiteScore: 13.9
Impact factor: 10.1
ISSN: 03043835, 18727980
PubMed ID:
28536009
Cancer Research
Oncology
Краткое описание
Melittin (MEL), a major peptide component of bee venom, is an attractive candidate for cancer therapy. This agent has shown a variety of anti-cancer effects in preclinical cell culture and animal model systems. Despite a convincing efficacy data against variety of cancers, its applicability to humans has met with challenges due to several issues including its non-specific cytotoxicity, degradation and hemolytic activity. Several optimization approaches including utilization of nanoparticle based delivery of MEL have been utilized to circumvent the issues. Here, we summarize the current understanding of the anticancer effects of bee venom and MEL on different kinds of cancers. Further, we also present the available information for the possible mechanism of action of bee venom and/or MEL.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Топ-30
Журналы
|
2
4
6
8
10
12
14
|
|
|
Toxins
13 публикаций, 4.35%
|
|
|
Toxicon
7 публикаций, 2.34%
|
|
|
Pharmaceutics
6 публикаций, 2.01%
|
|
|
International Journal of Molecular Sciences
6 публикаций, 2.01%
|
|
|
International Journal of Peptide Research and Therapeutics
6 публикаций, 2.01%
|
|
|
Molecules
5 публикаций, 1.67%
|
|
|
Antibiotics
5 публикаций, 1.67%
|
|
|
Cancers
4 публикации, 1.34%
|
|
|
Frontiers in Pharmacology
4 публикации, 1.34%
|
|
|
Scientific Reports
4 публикации, 1.34%
|
|
|
Journal of Controlled Release
4 публикации, 1.34%
|
|
|
Biomedicine and Pharmacotherapy
4 публикации, 1.34%
|
|
|
Journal of Drug Delivery Science and Technology
4 публикации, 1.34%
|
|
|
ACS applied materials & interfaces
4 публикации, 1.34%
|
|
|
Toxin Reviews
3 публикации, 1%
|
|
|
Oxidative Medicine and Cellular Longevity
3 публикации, 1%
|
|
|
International Journal of Biological Macromolecules
3 публикации, 1%
|
|
|
Biochemical Society Transactions
2 публикации, 0.67%
|
|
|
Biomolecules
2 публикации, 0.67%
|
|
|
Frontiers in Microbiology
2 публикации, 0.67%
|
|
|
Frontiers in Oncology
2 публикации, 0.67%
|
|
|
Nature Communications
2 публикации, 0.67%
|
|
|
Applied Microbiology and Biotechnology
2 публикации, 0.67%
|
|
|
PLoS ONE
2 публикации, 0.67%
|
|
|
European Journal of Pharmaceutical Sciences
2 публикации, 0.67%
|
|
|
Biomaterials
2 публикации, 0.67%
|
|
|
Bioorganic Chemistry
2 публикации, 0.67%
|
|
|
Advanced healthcare materials
2 публикации, 0.67%
|
|
|
Journal of Physical Chemistry B
2 публикации, 0.67%
|
|
|
2
4
6
8
10
12
14
|
Издатели
|
10
20
30
40
50
60
70
80
|
|
|
Elsevier
76 публикаций, 25.42%
|
|
|
MDPI
50 публикаций, 16.72%
|
|
|
Springer Nature
41 публикация, 13.71%
|
|
|
Wiley
22 публикации, 7.36%
|
|
|
Taylor & Francis
22 публикации, 7.36%
|
|
|
Frontiers Media S.A.
16 публикаций, 5.35%
|
|
|
American Chemical Society (ACS)
16 публикаций, 5.35%
|
|
|
Bentham Science Publishers Ltd.
7 публикаций, 2.34%
|
|
|
Hindawi Limited
6 публикаций, 2.01%
|
|
|
Royal Society of Chemistry (RSC)
5 публикаций, 1.67%
|
|
|
SAGE
3 публикации, 1%
|
|
|
IntechOpen
3 публикации, 1%
|
|
|
Portland Press
2 публикации, 0.67%
|
|
|
Public Library of Science (PLoS)
2 публикации, 0.67%
|
|
|
Spandidos Publications
2 публикации, 0.67%
|
|
|
American Society for Biochemistry and Molecular Biology
1 публикация, 0.33%
|
|
|
Huazhong University of Science and Technology
1 публикация, 0.33%
|
|
|
King Saud University
1 публикация, 0.33%
|
|
|
Asian Network for Scientific Information
1 публикация, 0.33%
|
|
|
Walter de Gruyter
1 публикация, 0.33%
|
|
|
Turkish Chemical Society
1 публикация, 0.33%
|
|
|
Bursa Uludag University
1 публикация, 0.33%
|
|
|
Korean Society for Biochemistry and Molecular Biology - BMB Reports
1 публикация, 0.33%
|
|
|
Zhejiang University Press
1 публикация, 0.33%
|
|
|
Impact Journals
1 публикация, 0.33%
|
|
|
Bashkir State Medical University
1 публикация, 0.33%
|
|
|
Cold Spring Harbor Laboratory
1 публикация, 0.33%
|
|
|
Medknow
1 публикация, 0.33%
|
|
|
American Physical Society (APS)
1 публикация, 0.33%
|
|
|
10
20
30
40
50
60
70
80
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.
Вы ученый?
Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
300
Всего цитирований:
300
Цитирований c 2024:
96
(32.11%)
Цитировать
ГОСТ |
RIS |
BibTex
Цитировать
ГОСТ
Скопировать
Rady I. et al. Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy // Cancer Letters. 2017. Vol. 402. pp. 16-31.
ГОСТ со всеми авторами (до 50)
Скопировать
Rady I., Siddiqui I. A., Rady M., Mukhtar H. Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy // Cancer Letters. 2017. Vol. 402. pp. 16-31.
Цитировать
RIS
Скопировать
TY - JOUR
DO - 10.1016/j.canlet.2017.05.010
UR - https://doi.org/10.1016/j.canlet.2017.05.010
TI - Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy
T2 - Cancer Letters
AU - Rady, Islam
AU - Siddiqui, Imtiaz A.
AU - Rady, Mohamad
AU - Mukhtar, Hasan
PY - 2017
DA - 2017/08/01
PB - Elsevier
SP - 16-31
VL - 402
PMID - 28536009
SN - 0304-3835
SN - 1872-7980
ER -
Цитировать
BibTex (до 50 авторов)
Скопировать
@article{2017_Rady,
author = {Islam Rady and Imtiaz A. Siddiqui and Mohamad Rady and Hasan Mukhtar},
title = {Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy},
journal = {Cancer Letters},
year = {2017},
volume = {402},
publisher = {Elsevier},
month = {aug},
url = {https://doi.org/10.1016/j.canlet.2017.05.010},
pages = {16--31},
doi = {10.1016/j.canlet.2017.05.010}
}